World Health Organization Issues Concern Over Critical Scarcity of Weight-Loss Jabs

Under 10% of individuals who could benefit from GLP-1 drugs like Wegovy have access to them, caution the global health agency as it releases its initial recommendations on the medications.

With more than one billion people worldwide now classified as obese, it is calling for increased and just availability to these injectable treatments.

According to projections, over two billion are projected to be living with obesity by 2030 unless action is taken.

"Our latest guidelines affirms that excess weight is a long-term condition that can be managed with thorough and continuous treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and logistical bottlenecks are major hurdles to broad access to the injections that can aid individuals in losing significant body mass, explains the body.

GLP-1 Therapy Scarcity

Even in the current most optimistic scenario, the production of such drugs might only reach about 100 million people – less than 10% of those who need them, as stated by the health organization.

The advice calls on countries and companies to expand access, by approaches like patent sharing.

Exclusive production rights on semaglutide – the primary component of a leading brand – is due to expire in a number of nations in 2026.

The Way Obesity Injections Function

GLP-1 drugs imitate a natural hormone to reduce digestion speed, reduce hunger and boost satiety so people eat less.

People commonly begin shedding pounds within a few weeks of commencing the regular doses.

Evidence points to people may put most of the weight back on within a year of discontinuing the treatment, because their usual appetite come back.

To be carrying excess weight elevates your risk for contracting health problems, such as diabetes, heart disease, brain attack, and specific malignancies.

Excess weight affects individuals in every country and was responsible for over three and a half million fatalities worldwide in 2024, as per the health agency.